Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Preceptorship on Ovarian Cancer 2024: Lisbon
- Start date
- 25 Sep 2024
- End date
- 26 Sep 2024
- Location
- Lisbon, Portugal
Learning objectives
- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side effects of treatment
Co-Chairs
- Jonathan A. Ledermann, United Kingdom
- Sven Mahner, Germany
Travel grant
In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros is offered to non-local participants as a contribution versus their travel costs (excluding Visa costs).
Participants must supply proof of travel as appropriate (tickets and receipts/invoices).
The reimbursement will be processed after the course according to the rules below:
Distance |
Reimbursement per return trip |
|---|---|
Up to 100 km |
EUR 70.00 |
101 > 399 km |
EUR 150.00 |
> 400 km |
Please visit this page and use the rail or flight calculator by inserting the city of departure and the city of arrival; then refer to Table 2 (on the same page) to check the reimbursement amount corresponding to the calculated distance. |
*Place of work | |
Accreditation
The programme of this event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Supported by
